Many trials and meta-analyses supported those conclusions: COX-2 inhibitors increased the risk of CV events by 42% [88,94], highly increased the risk of CV-related mortality (adjusted OR 0.54, 95% CI 0.34–0.86) [94], increased the risk of first-time myocardial infarction within 180 days of initiation of NSAIDs [95], and were associated with a higher relative risk of myocardial infarction with diclofenac and rofecoxib [96]. Here, PTGS2 is linked to myocardial infarction.